RESUMEN
Objective:To explore the effect of individualized occupational therapy on occupational performance of schizophrenic patients. Methods:From 2016 to 2018, 30 schizophrenic patients hospitalized over one year in Beijing Anding Hospital were randomly divided into control group (n = 15) and experimental group (n = 15). The control group was given routine group work activities, and the experimental group was given individualized occupational therapy, 30 minutes a time, once a day, five days a week for four weeks. The Comprehensive Occupational Therapy Evaluation Scale (COTE) was used to evaluate the occupational performance of schizophrenic patients before and after treatment。 Results:The difference value of COTE score was higher in the experimental group than in the control group (t = 3.842, P < 0.01), especially for interpersonal communication behavior and task behavior (t > 3.106, P < 0.01). Conclusion:Individualized occupational therapy could improve the occupational performance of patients with schizophrenia.
RESUMEN
OBJECTIVE: To use IFNα injection as inhalant for there is no proper dosage form for aerosol inhalation and evaluate the feasibility of IFN-α off-label use. METHODS: The clinical studies in SARS and MERS were reviewed to discuss the efficacy and safety of IFN-α application in COVID-19. Meanwhile, the features of aerosol inhalation, characteristics of IFN-α and related clinical researches were analyzed to argue the possibility of IFN-α aerosol inhalation. RESULTS: IFN-α seems to be effective in relieving early symptoms but likely invalid in reducing mortality of severe patients, however, the exact therapeutic effect calls for further clinical tests. Proper atomization of IFN-α injection won't reduce biological activity of the protein, but absorption and utilization of IFN-α in lung may be unsatisfactory for the lack of sorbefacient. More than that, ingredients in IFN-α injection may increase risk of adverse reaction. CONCLUSION: The aerosol inhalation of IFN-α injection should be fully evaluated on the side of patients. If there is a lack of proper atomization device or operation staff, subcutaneous injection of IFN-α may be a tentative administration.
RESUMEN
O cotidiano de uma pessoa que sofre de Síndrome Complexa de Dor Regional de tipo I (SCDR I) passa a ser limitado, pois essa síndrome gera sinais e sintomas localizados no membro acometido, podendo também se estabelecer em outros locais. Tendo isso em vista, este estudo objetiva apresentar as contribuições da Terapia Ocupacional e do Programa de Reabilitação Baseado no Estresse Muscular de Tração e Compressão Ativa para um sujeito com SCDR I no membro superior, atendido pelo Grupo de Dor do Hospital Universitário de Santa Maria (HUSM), RS. A presente pesquisa é caracterizada como um estudo de caso, experimental, que se ocupa dos períodos pré e pós-intervenção terapêutica ocupacional. Os instrumentos utilizados para coleta de dados foram os protocolos de Disfunção Ombro, Braço, Mão (DASH), a Classificação Internacional de Incapacidade, Funcionalidade e Saúde (CIF), a Medida Canadense de Desempenho Ocupacional (COPM), a Goniometria e a Escala Visual Analógica (EVA). Findas as avaliações, o sujeito foi exposto ao tratamento de exercícios ativos resistivos compressivos e, após a conclusão do tratamento, foi reavaliado. Observou-se, então, que o tratamento aplicado contribuiu para a diminuição do quadro doloroso e para a melhoria na Amplitude de Movimento (ADM) do sujeito. A utilização do protocolo de estresse e compressão ativa contribuiu significativamente para a redução da dor, o ganho de ADM e a melhora do desempenho ocupacional.
RESUMEN
La magnitud, velocidad y eficacia antihipertensiva de la nifedipina de liberación programada en microgránulos (NLPM) fue evaluada en pacientes con hipertensión moderada a severa. Un total de ciento treinta y cinco pacientes fueron evaluados durante seis semanas en un estudio prospectivo, abierto, comparativo y cruzado. 25.9% (n = 35) fueron pacientes controles normales, del resto eran pacientes hipertensos, 40% (n = 54 pacientes) recibieron 30 mgrs (8am ó 8pm) de NLPM y 20.7% (n = 28 pacientes) recibieron 60 mgrs (8am ó 8pm) de NLPM, el 13.3% de los pacientes admitidos (n = 18) fueron considerados como fracasos de la medicación. Ambas dosis a los distintos horarios de la toma disminuyeron significativamente las presiones arteriales (p < 0.05). En los pacientes que lograron el punto deseado con 30 mgrs, éste se logró desde la 3ra. semana de administrado el medicamento manteniéndose en los niveles tensionales buscados hasta el final del estudio, siendo la magnitud más elevada de reducción de: 8am PAS 15.5 mmHg (12.2%), PAD 12 mmHg (12.6%), PAM 12.2 mmHg (10.9%) y 8pm de: PAS 14.1 mmHg (9.7%), PAD 9.5 mmHg (10.6%) y PAM 11.2 mmHg (10.05%), en cambio en aquellos que lograron el punto deseado con la administración de 60 mgrs, se observaron reducciones desde la 3ra. semana obteniéndose el efecto máximo a la 6ta.semana siendo la magnitud más elevada de reducción de: 8am PAS 26.3 mmHg (16.34%), PAD 18.5 mmHg (17.69%) y PAM 20.9 mmHg (17.0%) y 8pm PAS 22.5 mmHg (15.15%), PAD 18 mmHg (18.1%) y PAM 21.8 mmHg (18.5%). La magnitud de la respuesta antihipertensiva de la NLPM fue numéricamente mayor con 60 mgrs que con 30 mgrs, pero la velocidad de respuesta fue mayor con 30 mgrs probablemente debido a que las cifras tensionales al inicio del estudio eran mayores en el grupo que requirió 60 mgrs, (p < 0.05) llegándose al final del estudio (6ta. semana) a cifras tensionales normales y similares en ambos grupos (p > 0.05). La FC en el grupo de 30 mgrs (8am y 8pm) mostró una disminución significativa luego del tratamiento (p < 0.05), en cambio en el grupo de 60 mgrs éstas se mantuvieron inalteradas (p > 0.05). En conclusión NLPM demostró ser eficaz para el manejo de los pacientes con hipertensión leve a moderada, obteniéndose con la dosis de 60 mgrs mayor magnitud en el efecto hipotensor que con la dosis de 30 mgrs, exhibiendo esta última mayor velocidad de respuesta antihipertensiva.
The magnitude, velocity and antihypertensive effectiveness of the nifedipine liberation programmed in microgranules (NLPM) was evaluated in patients with moderate to severe hypertension. A total of one hundred and thirty five patients were evaluated during six weeks in a prospective, open, comparative and crossed study. Of that group, 25.9% (n = 35) were normal patients, the remainder of them were hypertensive patients, 40% (n = 54 patients) received 30 mgrs (8am or 8pm) of NLPM and 20.7% (n = 28 patients) received 60 mgrs (8am or 8pm) of NLPM, 13.3% of the admitted patients (n = 18) were considered as failures of the medication. Both doses at different schedules of the taking diminished the arterial pressures significantly (p <0.05). There were patients that reached the end point a 30 mgrs dose, this achievement was obtained from the 3rd week of medication keeping on these pressure levels until the end of the study, being the highest magnitude of reduction were: 8am PAS 15.5 mmHg (12.2%), PAD 12 mmHg (12.6%), PAM 12.2 mmHg (10.9%) and 8pm of: PAS 14.1 mmHg (9.7%), PAD 9.5 mmHg (10.6%) and PAM 11.2 mmHg (10.05%), on the other hand, in those who achieved the end point with the administration of 60 mgrs, reductions were observed from the 3rd week obtaining the maximum effect at the 6th week being the highest magnitude of reduction of: 8am PAS 26.3 mmHg (16.34%), PAD 18.5 mmHg (17.69%) and PAM 20.9 mmHg (17.0%) and 8pm PAS 22.5 mmHg (15.15%), PAD 18 mmHg (18.1%) and PAM 21.8 mmHg (18.5%). The magnitude of the antihypertensive response of the NLPM was numerically bigger with 60 mgrs than with 30 mgrs, but the response velocity was bigger with 30 mgrs maybe because the blood pressure at the beginning of the study were bigger in that group that required 60 mgrs, (p <0.05) arriving at the end of the study (6th week) to normal pressure figure, similar in both groups (p> 0.05). The heart rate in the group of 30 mgrs (8am and 8pm) showed a significant decrease after the treatment (p <0.05), on the other hand in the group of 60 mgrs these stayed unaffected (p> 0.05). In conclusion NLPM demonstrated to be effective for the managing of patients with light to moderate hypertension, obtaining a bigger magnitude in the blood pressure effect with a dose of 60 mgrs than with a dose 30 mgrs, however, with this last dose, the antihypertensive response was more fast.
RESUMEN
This review summarizes the progress of therapy evaluation of schistosomiais with immunology methods and expects the application foreground of nucleic acid detecting methods.